The North America Wound Debridement Market should witness market growth of 5.0% CAGR during the forecast period (2022-2028).
Chronic wounds or chronic lower extremity ulcers do not heal progressively by using standard treatment and medications. As a consequence, chronic wounds pose a significant challenge to the healthcare system. Such wounds require extra care and specific treatment methods like wound debridement.
These wounds can be categorized as diabetic ulcers, vascular ulcers, and pressure ulcers (PUs). All these types of wounds share some common features like excessive or prolonged inflammation, formation of drug-resistant biofilms, response inability of epidermal and dermal cells to reparative stimuli, and persistent infections.
These pathophysiologic phenomena hinder the healing process of the wound. The only difference in all kinds of chronic wounds is in their underlying pathologies. As a result, to get improved clinical outcomes, it is necessary to address and understand the difficulties that arise in chronic wound treatments. This would subsequently help in reducing the cost of healthcare and improving the quality of life of patients.
The growing ulcer incidence in the region is the most prominent factor that raises the requirement for wound debridement products. For example, the Centers for Disease Control and Prevention (CDC) of the United States of America stated that approximately 37.3 million individuals in the nation suffer from diabetes. This has increased the prevalence of diabetic foot ulcers and venous ulcers among the general population.
The US market dominated the North America Wound Debridement Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $1, 650.7 million by 2028. The Canada market is poised to grow at a CAGR of 7.4% during (2022-2028). Additionally, The Mexico market should witness a CAGR of 6.5% during (2022-2028).
Based on Mode of Purchase, the market is segmented into Prescription, Over The Counter and Others. Based on Product, the market is segmented into Medical Gauzes, Gels, Surgical Devices, Ultrasonic Devices, Ointments & Creams and Others. Based on Method, the market is segmented into Surgical, Autolytic, Enzymatic, Mechanical and Others. Based on Wound Type, the market is segmented into Diabetic Foot Ulcers, Pressure Ulcers, Burn Wounds and Venous Leg Ulcers & Others. Based on End-use, the market is segmented into Hospitals, Homecare and Others. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include 3M Company, Coloplast Group, Medline Industries, Inc., Smith & Nephew PLC, Medtronic PLC, ConvaTec Group PLC, Integra LifeSciences Holdings Corporation (Derma Sciences, Inc.), Johnson & Johnson (Ethicon, Inc.), Baxter International, Inc., and Molnlycke Health Care AB.
Chronic wounds or chronic lower extremity ulcers do not heal progressively by using standard treatment and medications. As a consequence, chronic wounds pose a significant challenge to the healthcare system. Such wounds require extra care and specific treatment methods like wound debridement.
These wounds can be categorized as diabetic ulcers, vascular ulcers, and pressure ulcers (PUs). All these types of wounds share some common features like excessive or prolonged inflammation, formation of drug-resistant biofilms, response inability of epidermal and dermal cells to reparative stimuli, and persistent infections.
These pathophysiologic phenomena hinder the healing process of the wound. The only difference in all kinds of chronic wounds is in their underlying pathologies. As a result, to get improved clinical outcomes, it is necessary to address and understand the difficulties that arise in chronic wound treatments. This would subsequently help in reducing the cost of healthcare and improving the quality of life of patients.
The growing ulcer incidence in the region is the most prominent factor that raises the requirement for wound debridement products. For example, the Centers for Disease Control and Prevention (CDC) of the United States of America stated that approximately 37.3 million individuals in the nation suffer from diabetes. This has increased the prevalence of diabetic foot ulcers and venous ulcers among the general population.
The US market dominated the North America Wound Debridement Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $1, 650.7 million by 2028. The Canada market is poised to grow at a CAGR of 7.4% during (2022-2028). Additionally, The Mexico market should witness a CAGR of 6.5% during (2022-2028).
Based on Mode of Purchase, the market is segmented into Prescription, Over The Counter and Others. Based on Product, the market is segmented into Medical Gauzes, Gels, Surgical Devices, Ultrasonic Devices, Ointments & Creams and Others. Based on Method, the market is segmented into Surgical, Autolytic, Enzymatic, Mechanical and Others. Based on Wound Type, the market is segmented into Diabetic Foot Ulcers, Pressure Ulcers, Burn Wounds and Venous Leg Ulcers & Others. Based on End-use, the market is segmented into Hospitals, Homecare and Others. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include 3M Company, Coloplast Group, Medline Industries, Inc., Smith & Nephew PLC, Medtronic PLC, ConvaTec Group PLC, Integra LifeSciences Holdings Corporation (Derma Sciences, Inc.), Johnson & Johnson (Ethicon, Inc.), Baxter International, Inc., and Molnlycke Health Care AB.
Scope of the Study
By Mode of Purchase
- Prescription
- Over The Counter
- Others
By Product
- Medical Gauzes
- Gels
- Surgical Devices
- Ultrasonic Devices
- Ointments & Creams
- Others
By Method
- Surgical
- Autolytic
- Enzymatic
- Mechanical
- Others
By Wound Type
- Diabetic Foot Ulcers
- Pressure Ulcers
- Burn Wounds
- Venous Leg Ulcers & Others
By End-use
- Hospitals
- Homecare
- Others
By Country
- US
- Canada
- Mexico
- Rest of North America
Key Market Players
List of Companies Profiled in the Report:
- 3M Company
- Coloplast Group
- Medline Industries, Inc.
- Smith & Nephew PLC
- Medtronic PLC
- ConvaTec Group PLC
- Integra LifeSciences Holdings Corporation (Derma Sciences, Inc.)
- Johnson & Johnson (Ethicon, Inc.)
- Baxter International, Inc.
- Molnlycke Health Care AB
Unique Offerings
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 North America Wound Debridement Market, by Mode of Purchase
1.4.2 North America Wound Debridement Market, by Product
1.4.3 North America Wound Debridement Market, by Method
1.4.4 North America Wound Debridement Market, by Wound Type
1.4.5 North America Wound Debridement Market, by End-use
1.4.6 North America Wound Debridement Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Competition Analysis - Global
3.1 Cardinal Matrix
3.2 Recent Industry Wide Strategic Developments
3.2.1 Partnerships, Collaborations and Agreements
3.2.2 Product Launches and Product Expansions
3.2.3 Acquisition and Mergers
3.2.4 Geographical Expansions
3.3 Top Winning Strategies
3.3.1 Key Leading Strategies: Percentage Distribution (2018-2022)
Chapter 4. North America Wound Debridement Market by Mode of Purchase
4.1 North America Prescription Market by Country
4.2 North America Over The Counter Market by Country
4.3 North America Others Market by Country
Chapter 5. North America Wound Debridement Market by Product
5.1 North America Medical Gauzes Market by Country
5.2 North America Gels Market by Country
5.3 North America Surgical Devices Market by Country
5.4 North America Ultrasonic Devices Market by Country
5.5 North America Ointments & Creams Market by Country
5.6 North America Others Market by Country
Chapter 6. North America Wound Debridement Market by Method
6.1 North America Surgical Market by Country
6.2 North America Autolytic Market by Country
6.3 North America Enzymatic Market by Country
6.4 North America Mechanical Market by Country
6.5 North America Others Market by Country
Chapter 7. North America Wound Debridement Market by Wound Type
7.1 North America Diabetic Foot Ulcers Market by Country
7.2 North America Pressure Ulcers Market by Country
7.3 North America Burn Wounds Market by Country
7.4 North America Venous Leg Ulcers & Others Market by Country
Chapter 8. North America Wound Debridement Market by End-use
8.1 North America Hospitals Market by Country
8.2 North America Homecare Market by Country
8.3 North America Others Market by Country
Chapter 9. North America Wound Debridement Market by Country
9.1 US Wound Debridement Market
9.1.1 US Wound Debridement Market by Mode of Purchase
9.1.2 US Wound Debridement Market by Product
9.1.3 US Wound Debridement Market by Method
9.1.4 US Wound Debridement Market by Wound Type
9.1.5 US Wound Debridement Market by End-use
9.2 Canada Wound Debridement Market
9.2.1 Canada Wound Debridement Market by Mode of Purchase
9.2.2 Canada Wound Debridement Market by Product
9.2.3 Canada Wound Debridement Market by Method
9.2.4 Canada Wound Debridement Market by Wound Type
9.2.5 Canada Wound Debridement Market by End-use
9.3 Mexico Wound Debridement Market
9.3.1 Mexico Wound Debridement Market by Mode of Purchase
9.3.2 Mexico Wound Debridement Market by Product
9.3.3 Mexico Wound Debridement Market by Method
9.3.4 Mexico Wound Debridement Market by Wound Type
9.3.5 Mexico Wound Debridement Market by End-use
9.4 Rest of North America Wound Debridement Market
9.4.1 Rest of North America Wound Debridement Market by Mode of Purchase
9.4.2 Rest of North America Wound Debridement Market by Product
9.4.3 Rest of North America Wound Debridement Market by Method
9.4.4 Rest of North America Wound Debridement Market by Wound Type
9.4.5 Rest of North America Wound Debridement Market by End-use
Chapter 10. Company Profiles
10.1 Medtronic PLC
10.1.1 Company overview
10.1.2 Financial Analysis
10.1.3 Segmental and Regional Analysis
10.1.4 Research & Development Expenses
10.1.5 Recent strategies and developments:
10.1.5.1 Partnerships, Collaborations, and Agreements:
10.1.6 SWOT Analysis
10.2 ConvaTec Group PLC
10.2.1 Company Overview
10.2.2 Financial Analysis
10.2.3 Product Category and Regional Analysis
10.2.4 Research & Development Expense
10.2.5 Recent strategies and developments:
10.2.5.1 Partnerships, Collaborations, and Agreements:
10.2.5.2 Acquisitions and Mergers:
10.2.5.3 Product Launches and Expansions:
10.3 Coloplast Group
10.3.1 Company Overview
10.3.2 Financial Analysis
10.3.3 Segmental and Regional Analysis
10.3.4 Research & Development Expense
10.4 3M Company
10.4.1 Company Overview
10.4.2 Financial Analysis
10.4.3 Segmental and Regional Analysis
10.4.4 Research & Development Expense
10.4.5 Recent strategies and developments:
10.4.5.1 Acquisitions and Mergers:
10.5 Smith & Nephew PLC
10.5.1 Company Overview
10.5.2 Financial Analysis
10.5.3 Segmental Analysis
10.5.4 Research & Development Expense
10.5.5 Recent strategies and developments:
10.5.5.1 Geographical Expansions:
10.5.5.2 Acquisitions and Mergers:
10.6 Integra LifeSciences Holdings Corporation (Derma Sciences, Inc.)
10.6.1 Company Overview
10.6.2 Financial Analysis
10.6.3 Segmental and Regional Analysis
10.6.4 Research & Development Expense
10.7 Baxter International, Inc.
10.7.1 Company Overview
10.7.2 Financial Analysis
10.7.3 Segmental Analysis
10.7.4 Research & Development Expense
10.7.5 Recent strategies and developments:
10.7.5.1 Acquisition and Mergers:
10.8 Johnson & Johnson (Ethicon, Inc.)
10.8.1 Company Overview
10.8.2 Financial Analysis
10.8.3 Segmental &Regional Analysis
10.8.4 Research & Development Expenses
10.8.5 Recent strategies and developments:
10.8.5.1 Acquisition and Mergers:
10.9 Medline Industries, Inc.
10.9.1 Company Overview
10.9.2 Recent strategies and developments:
10.9.2.1 Partnerships, Collaborations, and Agreements:
10.10. Molnlycke Health Care AB
10.10.1 Company Overview
10.10.2 Recent strategies and developments:
10.10.2.1 Partnerships, Collaborations, and Agreements:
Companies Mentioned
- 3M Company
- Coloplast Group
- Medline Industries, Inc.
- Smith & Nephew PLC
- Medtronic PLC
- ConvaTec Group PLC
- Integra LifeSciences Holdings Corporation (Derma Sciences, Inc.)
- Johnson & Johnson (Ethicon, Inc.)
- Baxter International, Inc.
- Molnlycke Health Care AB
